Treating mild hypothyroidism: Benefits still uncertain

More than 10 million adults in the US have hypothyroidism — when the thyroid gland fails to produce enough thyroid hormone to meet the body’s needs — but the vast majority of these cases are considered mild. Whether or not to treat mild hypothyroidism is an ongoing debate. There is a possible link between mild hypothyroidism and coronary artery disease, but researchers found that treating it in older people did not provide any benefit. The post Treating mild hypothyroidism: Benefits still uncertain appeared first on Harvard Health Blog.

Treating mild hypothyroidism: Benefits still uncertain

Your thyroid, a tiny, butterfly-shaped gland located in front of your windpipe (trachea) and below your voice box (larynx) can have a profound impact on your health and well-being. Throughout life, your thyroid is constantly producing hormones that influence your metabolism. These hormones affect your mood, energy, body temperature, weight, heart, and more.

A brief overview of hypothyroidism

Your thyroid produces two kinds of thyroid hormones: T4, or thyroxine, and T3, or triiodothyronine. These hormones influence every cell, tissue, and organ in your body, from your muscles, bones, and skin to your digestive tract, brain, and heart, by controlling how fast and efficiently cells convert nutrients into energy — a chemical activity known as metabolism.

The thyroid gland is under the influence of the pituitary gland. No larger than a pea and located at the base of the brain, the pituitary gland controls your thyroid’s production of thyroid hormone by releasing thyroid stimulating hormone (TSH).

TSH levels in your bloodstream rise or fall depending on whether there is enough thyroid hormone made to meet your body’s needs. Higher levels of TSH prompt the thyroid to produce more thyroid hormone, while lower levels signal the thyroid to produce less.

Hypothyroidism occurs when the thyroid fails to produce enough thyroid hormone to meet the body’s needs, thereby slowing metabolism. In someone with overt hypothyroidism, thyroid hormone levels are below normal and TSH levels are well above the normal range.

What is mild hypothyroidism?

Subclinical, or mild, hypothyroidism doesn’t meet the standard definition of hypothyroidism. In mild hypothyroidism, you may or may not have symptoms and your levels of T4 and T3 are normal, but your TSH levels are slightly elevated. Mild hypothyroidism is diagnosed by a blood test.

More than 10 million adults in the US have hypothyroidism, the vast majority of which is subclinical.

What are the risks of leaving mild hypothyroidism untreated?

Whether or not to treat mild hypothyroidism is a subject that has been studied and debated for years. What worries doctors most about mild hypothyroidism is the potential link between untreated mild hypothyroidism and coronary artery disease. Results of research on whether subclinical thyroid disease causes heart problems have been conflicting. The condition has been associated with heart and blood vessel abnormalities, and studies indicate that treating mild hypothyroidism can improve various markers of heart structure and function.

However, a recent study published in the Journal of the American Medical Association may give doctors pause. The researchers studied people with mild hypothyroidism who had also had a heart attack. They treated one group of these patients for their mild hypothyroidism, and left the condition untreated in the other group. The study showed that those treated for mild hypothyroidism did not have better heart function than those who were not treated.

What are the downsides of treating mild hypothyroidism?

When mild hypothyroidism is treated, levothyroxine (T4) is the treatment of choice.

A 2017 trial published in The New England Journal of Medicine found that treating people ages 65 and older for mild hypothyroidism doesn’t have much of a benefit. The authors found no real differences in symptoms between participants who received levothyroxine and those who got a placebo. The authors say many older adults revert to normal thyroid function on their own, without treatment. A follow-up study recently published in the Annals of Internal Medicine analyzed data from patients enrolled in the 2017 NEJM study, and determined that even those with the greatest number of symptoms did not benefit.

In addition to the possibility that the treatment may not offer any benefit, there are other reasons for caution. Overtreatment — prescribing thyroid medication to someone with subclinical disease who may not need treatment, or giving excessive thyroid medication — comes with serious risks, particularly thyrotoxicosis, the presence of too much thyroid hormone in the body. This happens frequently; estimates suggest 20% or more of those treated with thyroid hormone experience thyrotoxicosis. Long-term complications of even mild thyrotoxicosis can include heart problems and bone loss.

Considering the risks and benefits of treatment

If you are weighing the pros and cons of treatment for hypothyroidism, discuss the following questions with your doctor:

  • How might I benefit from treatment? Could it treat my symptoms? Prevent heart disease? Help me conceive?
  • What are the risks of treatment?
  • How will we know if treatment is working, and how long will it take to determine this?
  • For how long will I need to continue treatment?

The post Treating mild hypothyroidism: Benefits still uncertain appeared first on Harvard Health Blog.

Source : Harvard Health More   

What's Your Reaction?


Next Article

Alarming Data Show a Third Wave of COVID-19 Is About to Hit the U.S.

America's battle with COVID-19 is not even close to finished

Alarming Data Show a Third Wave of COVID-19 Is About to Hit the U.S.

There are few things as powerful as avoidance learning. Touch a hot stove once and you’re not likely to do it again. Cross against the light and almost get hit by a car and you’re going to be a lot more careful the next time. But when it comes to the U.S. response to COVID-19? Not so much.

You’d have thought that the sight of overflow hospital tents and refrigerated trucks to hold victims’ bodies in New York would have been enough to scare us all straight in mid-March and early April, when infection rates peaked at 32,000 new cases a day, or nearly 10 cases per 100,000 residents—making social distancing, mask-wearing and hand-washing all universal practices. But shortly after that peak, the warm weather arrived and several states cautiously reopened some public spaces for Memorial Day.

That, as we wrote at the time, quickly led to distressing signs of upticks in several states, pushing the national rate marginally north again. By the end of June, the rolling average of new cases per day had far exceeded the April peak, prompting some states to pull back their reopening plans. But the damage had been done. By mid-July, a second wave peaked at over twice the value of the first, exceeding 67,000 cases per day—more than 20 cases per capita. There was good news buried in that bad news, however: after the peak was reached, the decline was at least quicker and more precipitous than it was the first time.

But now for the worse news: Heading into the fall and winter, there are clear signs of a third resurgence bearing a close resemblance to what we saw in early June. Since the most recent nadir on Sept. 9, when the national rate was at 34,300 cases a day—still a notch above the April peak—cases have risen to 45,300 a day, a 32% increase. The numbers paint an alarmingly familiar picture that spells trouble ahead—despite President Donald Trump’s repeated but false assertions that the country is “rounding the final turn” on the pandemic.

“The latest information is that 90% of the country has not yet been exposed to the virus,” says Dr. Tom Inglesby, director of the Johns Hopkins Center for Health Security at the Bloomberg School of Public Health. “The virus hasn’t changed and has the capacity to spread rapidly if given a chance.”

It’s now getting that chance. The politicization of mask-wearing; conflicting guidelines from the White House, the Centers for Disease Control and Prevention and the Food and Drug Administration; and state and local policies that contribute to viral transmission are helping to do the disease’s work for it.

“A single and coordinated strategy might have brought us to a different place,” says Dr. Jon Samet, dean of the Colorado School of Public Health. “Even within some states, counties may proceed independently. There is wide variation in the credence given to misinformation, some sourced from the Administration and even the President.”

Samet’s own state offers a vivid example of the rise of the third wave, with its graph since spring forming a stark, three-peaked mountain range, not unlike a view you might find while hiking in the Colorado Rockies:

In some ways, however, Colorado is an outlier in the new wave—or at least lies at its very vanguard. The first wave hit hardest in the Northeast; the second in the South and the West. Now, even as cases balloon in the South again (driven in large part by Texas and Florida), the Midwest has surpassed the West in cases, with dramatic spikes from Wisconsin and Minnesota to the Dakotas and down to Utah and Wyoming:

At a more granular level, the geographic trends become even clearer. There are more than 3,000 counties (or county-equivalents, like parishes) in the U.S., almost all of which report individual daily figures for new COVID-19 positive tests. Breaking them down into three categories—small, medium and large, each with about a third of the U.S. population—reveals that the 62 largest counties, which are home to 110 million people, were responsible for more cases than either of the other two categories through mid-August. Now the story has flipped, with the bloc of smallest counties—encompassing the same number of total people but distributed across a much larger, more rural geography—contributing the most new cases:

“Given that these are rural areas, behaviors of individuals are likely to be a dominant driver: not adhering to distancing and not wearing masks,” says Samet. “Checking across mask orders in these states, there is a wide range. I suspect adherence to use of masks is lower in these rural counties than in urban areas, as in Colorado by anecdotal reports.”

There has also been a shift in COVID-19 age demographics that in turn affect the regional situation. “In part of the Midwest, the rise is being driven by young adults who seem to have gotten the coronavirus in universities,” says Inglesby. It doesn’t help that college students—who are by nature less risk-averse than older people—are being enabled in their heedlessness by a lack of guidance from adults who ought to know better. It’s also worth noting that many young Americans hold jobs that increase exposure risk, like retail or restaurant work.

Whatever the manifold causes of the third wave, there is reason to worry that it will prove worse than the first two. The arrival of colder weather in some states means more time spent indoors, where viruses are more easily transmitted by aerosols produced when people sneeze, cough or merely speak. With the pandemic still raging, many people will likely scrap seasonal travel and family get-togethers for Thanksgiving, Christmas and so on—but many are likely to press ahead regardless, meaning minimal social distancing in crowded planes and trains and around holiday dinner tables.

“We are concerned that there could be a holiday spike with severity depending on where the epidemic curve is positioned before the start of the season in later November,” says Samet.

Whether the third wave will be followed by a fourth is, paradoxically, both impossible to say and entirely within our control. Hopefully, greater policy coherence from Washington, uniform national rules around masking and distancing, and broad public acceptance of an eventual vaccine—once it is proven to be safe and effective—will all, at last, stuff the COVID-19 genie back into its bottle. Until then, the U.S., which represents only 4% of the world’s population yet has reported more than 20% of its COVID-9 cases and deaths, will continue to struggle. It is up to all of us, working together, to bring that suffering to an end.

Source : Time More   

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.